Today, 34,654 Shares of Stock are sold by Five Prime Therapeutics Inc. (FPRX) Insider Francis Willard Sarena

Today, 34,654 Shares of Stock are sold by Five Prime Therapeutics Inc. (FPRX) Insider Francis Willard Sarena

Five Prime Therapeutics Inc. (NASDAQ:FPRX) insider Francis Willard Sarena sold 34,654 shares of Five Prime Therapeutics stock in a transaction on Friday, November 25th. The shares were sold at an average price of $60.38, for a total transaction of $2,092,408.52. Following the completion of the transaction, the insider now directly owns 94,731 shares of the company’s stock, valued at approximately $5,719,857.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Five Prime Therapeutics Inc. (NASDAQ:FPRX) opened at 58.635 on Tuesday. Five Prime Therapeutics Inc. has a 52-week low of $28.01 and a 52-week high of $60.98. The company’s 50-day moving average is $52.11 and its 200-day moving average is $47.66. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of 6.551 and a beta of 4.48.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($0.72) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.51) by $0.21. The firm had revenue of $6.70 million for the quarter, compared to analysts’ expectations of $7.50 million. Five Prime Therapeutics had a return on equity of 59.23% and a net margin of 64.94%. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.93) EPS. Equities analysts predict that Five Prime Therapeutics Inc. will post ($2.18) earnings per share for the current year.

Several analysts have recently issued reports on the stock. Citigroup Inc. assumed coverage on shares of Five Prime Therapeutics in a research report on Tuesday, October 25th. They issued a “buy” rating and a $65.00 target price on the stock. Credit Suisse Group AG reiterated a “buy” rating and issued a $54.00 target price on shares of Five Prime Therapeutics in a research report on Monday, November 7th. Jefferies Group set a $60.00 target price on shares of Five Prime Therapeutics and gave the company a “buy” rating in a research report on Friday, August 5th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $58.00 target price (up previously from $45.00) on shares of Five Prime Therapeutics in a research report on Monday, August 8th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $54.43.

Institutional investors have recently made changes to their positions in the company. FMR LLC increased its position in shares of Five Prime Therapeutics by 24.1% in the second quarter. FMR LLC now owns 2,817,208 shares of the company’s stock worth $116,492,000 after buying an additional 547,808 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Five Prime Therapeutics by 43.5% in the second quarter. Vanguard Group Inc. now owns 1,472,276 shares of the company’s stock worth $60,877,000 after buying an additional 446,311 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Five Prime Therapeutics by 1.6% in the third quarter. Acadian Asset Management LLC now owns 1,111,332 shares of the company’s stock worth $58,332,000 after buying an additional 16,964 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Five Prime Therapeutics by 7.1% in the third quarter. BlackRock Fund Advisors now owns 1,080,243 shares of the company’s stock worth $56,702,000 after buying an additional 71,528 shares during the last quarter. Finally, State Street Corp increased its position in shares of Five Prime Therapeutics by 28.5% in the second quarter. State Street Corp now owns 1,057,836 shares of the company’s stock worth $43,741,000 after buying an additional 234,648 shares during the last quarter. Institutional investors own 95.40% of the company’s stock.

About Five Prime Therapeutics

Related posts

Leave a Comment